SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '2q0a'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1CD2_A_FOLA307_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	6 / 12	ILE A 545 ALA A 593 PHE A 580 LEU A 603 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None None PCG A 401 (-2.9A)	1.22A	1cd2A-2q0aA: undetectable	1cd2A-2q0aA: 18.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RA2_A_FOLA161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	0.99A	1ra2A-2q0aA: undetectable	1ra2A-2q0aA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RA8_A_FOLA161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	6 / 12	ILE A 545 ALA A 593 PHE A 580 LEU A 603 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None None PCG A 401 (-2.9A)	1.24A	1ra8A-2q0aA: undetectable	1ra8A-2q0aA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RB2_A_FOLA161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.03A	1rb2A-2q0aA: undetectable	1rb2A-2q0aA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RB2_B_FOLB161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.04A	1rb2B-2q0aA: undetectable	1rb2B-2q0aA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RE7_A_FOLA161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.02A	1re7A-2q0aA: undetectable	1re7A-2q0aA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1RX2_A_FOLA161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	0.97A	1rx2A-2q0aA: undetectable	1rx2A-2q0aA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1WRL_E_TFPE212_1 (TROPONIN C, SLOW SKELETAL AND CARDIAC MUSCLES)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	4 / 7	PHE A 518 LEU A 586 PHE A 525 MET A 529	None	0.95A	1wrlE-2q0aA: undetectable	1wrlE-2q0aA: 19.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2C8A_B_NCAB1246_0 (MONO-ADP-RIBOSYLTRAN SFERASE C3)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	4 / 7	GLY A 581 SER A 605 ARG A 591 GLU A 536	PCG A 401 (-3.3A) None PCG A 401 (-4.0A) None	1.02A	2c8aB-2q0aA: undetectable	2c8aB-2q0aA: 24.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2D0K_A_FOLA1161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	6 / 12	ILE A 545 ALA A 593 ILE A 557 LEU A 603 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None None PCG A 401 (-2.9A)	1.41A	2d0kA-2q0aA: undetectable	2d0kA-2q0aA: 22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2D0K_A_FOLA1161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	6 / 12	ILE A 545 ALA A 593 PHE A 580 LEU A 603 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None None PCG A 401 (-2.9A)	1.23A	2d0kA-2q0aA: undetectable	2d0kA-2q0aA: 22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2D0K_B_FOLB2161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	6 / 12	ILE A 545 ALA A 593 ILE A 557 LEU A 603 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None None PCG A 401 (-2.9A)	1.39A	2d0kB-2q0aA: undetectable	2d0kB-2q0aA: 22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2D0K_B_FOLB2161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	6 / 12	ILE A 545 ALA A 593 PHE A 580 LEU A 603 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None None PCG A 401 (-2.9A)	1.20A	2d0kB-2q0aA: undetectable	2d0kB-2q0aA: 22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2F9W_A_PAUA6002_0 (PANTOTHENATE KINASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	4 / 8	ARG A 590 THR A 587 GLY A 551 ILE A 583	None None None PCG A 401 (-3.0A)	0.94A	2f9wA-2q0aA: undetectable 2f9wB-2q0aA: undetectable	2f9wA-2q0aA: 19.26 2f9wB-2q0aA: 19.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2W3A_B_TOPB1189_1 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 10	ILE A 545 ALA A 593 PHE A 580 LEU A 603 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.24A	2w3aB-2q0aA: undetectable	2w3aB-2q0aA: 23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2W3M_B_FOLB1188_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 LEU A 603 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.31A	2w3mB-2q0aA: undetectable	2w3mB-2q0aA: 23.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IA4_A_MTXA164_2 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	4 / 4	ILE A 545 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) None None PCG A 401 (-2.9A)	0.98A	3ia4A-2q0aA: undetectable	3ia4A-2q0aA: 23.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3QGT_B_CP6B609_1 (BIFUNCTIONAL DIHYDROFOLATE REDUCTASE-THYMIDYLAT E SYNTHASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 10	ILE A 545 ALA A 593 ILE A 557 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.29A	3qgtB-2q0aA: undetectable	3qgtB-2q0aA: 14.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3QJ7_A_SPMA264_1 (THYMIDYLATE SYNTHASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	4 / 8	ALA A 624 LEU A 517 ASP A 631 TYR A 579	None	0.95A	3qj7A-2q0aA: undetectable 3qj7D-2q0aA: undetectable	3qj7A-2q0aA: 22.05 3qj7D-2q0aA: 22.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TQ8_A_TOPA2001_1 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 9	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.06A	3tq8A-2q0aA: undetectable	3tq8A-2q0aA: 19.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4CD2_A_FOLA207_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 LEU A 603 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.21A	4cd2A-2q0aA: undetectable	4cd2A-2q0aA: 18.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4KJL_A_FOLA201_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	6 / 12	ILE A 545 ALA A 593 PHE A 580 LEU A 603 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None None PCG A 401 (-2.9A)	1.32A	4kjlA-2q0aA: undetectable	4kjlA-2q0aA: 22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4KM0_A_CP6A201_1 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 10	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.01A	4km0A-2q0aA: undetectable	4km0A-2q0aA: 20.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4KM0_B_CP6B201_1 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.02A	4km0B-2q0aA: undetectable	4km0B-2q0aA: 20.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4PTJ_A_FOLA201_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	0.96A	4ptjA-2q0aA: undetectable	4ptjA-2q0aA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4X5J_A_FOLA201_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.05A	4x5jA-2q0aA: undetectable	4x5jA-2q0aA: 24.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5E8Q_A_FOLA201_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.05A	5e8qA-2q0aA: undetectable	5e8qA-2q0aA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Z6J_A_FOLA201_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	0.96A	5z6jA-2q0aA: undetectable	5z6jA-2q0aA: 24.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Z6K_A_FOLA201_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 12	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	0.97A	5z6kA-2q0aA: undetectable	5z6kA-2q0aA: 24.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Z6M_A_FOLA201_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	5 / 11	ILE A 545 ALA A 593 PHE A 580 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None PCG A 401 (-2.9A)	1.06A	5z6mA-2q0aA: undetectable	5z6mA-2q0aA: 24.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	7DFR_A_FOLA161_0 (DIHYDROFOLATE REDUCTASE)	2q0a	POTASSIUM/SODIUM HYPERPOLARIZATION-AC TIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2 (Mus musculus)	6 / 12	ILE A 545 ALA A 593 PHE A 580 LEU A 603 ILE A 544 THR A 592	PCG A 401 ( 4.0A) PCG A 401 (-3.8A) None None None PCG A 401 (-2.9A)	1.25A	7dfrA-2q0aA: undetectable	7dfrA-2q0aA: 23.38

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1CD2_A_FOLA307_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",6,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;None;PCG A 401 (-2.9A)","1.22A","1cd2A-2q0aA:undetectable","1cd2A-2q0aA:18.55"],["1RA2_A_FOLA161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","0.99A","1ra2A-2q0aA:undetectable","1ra2A-2q0aA:23.38"],["1RA8_A_FOLA161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",6,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;None;PCG A 401 (-2.9A)","1.24A","1ra8A-2q0aA:undetectable","1ra8A-2q0aA:23.38"],["1RB2_A_FOLA161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.03A","1rb2A-2q0aA:undetectable","1rb2A-2q0aA:23.38"],["1RB2_B_FOLB161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.04A","1rb2B-2q0aA:undetectable","1rb2B-2q0aA:23.38"],["1RE7_A_FOLA161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.02A","1re7A-2q0aA:undetectable","1re7A-2q0aA:23.38"],["1RX2_A_FOLA161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","0.97A","1rx2A-2q0aA:undetectable","1rx2A-2q0aA:23.38"],["1WRL_E_TFPE212_1","TROPONIN C, SLOW SKELETAL AND CARDIAC MUSCLES","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",4,"PHE A 518;LEU A 586;PHE A 525;MET A 529","None","0.95A","1wrlE-2q0aA:undetectable","1wrlE-2q0aA:19.80"],["2C8A_B_NCAB1246_0","MONO-ADP-RIBOSYLTRANSFERASE C3","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",4,"GLY A 581;SER A 605;ARG A 591;GLU A 536","PCG A 401 (-3.3A);None;PCG A 401 (-4.0A);None","1.02A","2c8aB-2q0aA:undetectable","2c8aB-2q0aA:24.27"],["2D0K_A_FOLA1161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",6,"ILE A 545;ALA A 593;ILE A 557;LEU A 603;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;None;PCG A 401 (-2.9A)","1.41A","2d0kA-2q0aA:undetectable","2d0kA-2q0aA:22.39"],["2D0K_A_FOLA1161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",6,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;None;PCG A 401 (-2.9A)","1.23A","2d0kA-2q0aA:undetectable","2d0kA-2q0aA:22.39"],["2D0K_B_FOLB2161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",6,"ILE A 545;ALA A 593;ILE A 557;LEU A 603;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;None;PCG A 401 (-2.9A)","1.39A","2d0kB-2q0aA:undetectable","2d0kB-2q0aA:22.39"],["2D0K_B_FOLB2161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",6,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;None;PCG A 401 (-2.9A)","1.20A","2d0kB-2q0aA:undetectable","2d0kB-2q0aA:22.39"],["2F9W_A_PAUA6002_0","PANTOTHENATE KINASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",4,"ARG A 590;THR A 587;GLY A 551;ILE A 583","None;None;None;PCG A 401 (-3.0A)","0.94A","2f9wA-2q0aA:undetectable;2f9wB-2q0aA:undetectable","2f9wA-2q0aA:19.26;2f9wB-2q0aA:19.26"],["2W3A_B_TOPB1189_1","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.24A","2w3aB-2q0aA:undetectable","2w3aB-2q0aA:23.18"],["2W3M_B_FOLB1188_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.31A","2w3mB-2q0aA:undetectable","2w3mB-2q0aA:23.18"],["3IA4_A_MTXA164_2","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",4,"ILE A 545;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);None;None;PCG A 401 (-2.9A)","0.98A","3ia4A-2q0aA:undetectable","3ia4A-2q0aA:23.22"],["3QGT_B_CP6B609_1","BIFUNCTIONAL DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYNTHASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;ILE A 557;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.29A","3qgtB-2q0aA:undetectable","3qgtB-2q0aA:14.87"],["3QJ7_A_SPMA264_1","THYMIDYLATE SYNTHASE;THYMIDYLATE SYNTHASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",4,"ALA A 624;LEU A 517;ASP A 631;TYR A 579","None","0.95A","3qj7A-2q0aA:undetectable;3qj7D-2q0aA:undetectable","3qj7A-2q0aA:22.05;3qj7D-2q0aA:22.05"],["3TQ8_A_TOPA2001_1","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.06A","3tq8A-2q0aA:undetectable","3tq8A-2q0aA:19.50"],["4CD2_A_FOLA207_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.21A","4cd2A-2q0aA:undetectable","4cd2A-2q0aA:18.55"],["4KJL_A_FOLA201_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",6,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;None;PCG A 401 (-2.9A)","1.32A","4kjlA-2q0aA:undetectable","4kjlA-2q0aA:22.39"],["4KM0_A_CP6A201_1","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.01A","4km0A-2q0aA:undetectable","4km0A-2q0aA:20.67"],["4KM0_B_CP6B201_1","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.02A","4km0B-2q0aA:undetectable","4km0B-2q0aA:20.67"],["4PTJ_A_FOLA201_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","0.96A","4ptjA-2q0aA:undetectable","4ptjA-2q0aA:23.38"],["4X5J_A_FOLA201_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.05A","4x5jA-2q0aA:undetectable","4x5jA-2q0aA:24.51"],["5E8Q_A_FOLA201_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.05A","5e8qA-2q0aA:undetectable","5e8qA-2q0aA:23.38"],["5Z6J_A_FOLA201_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","0.96A","5z6jA-2q0aA:undetectable","5z6jA-2q0aA:24.51"],["5Z6K_A_FOLA201_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","0.97A","5z6kA-2q0aA:undetectable","5z6kA-2q0aA:24.51"],["5Z6M_A_FOLA201_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",5,"ILE A 545;ALA A 593;PHE A 580;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;PCG A 401 (-2.9A)","1.06A","5z6mA-2q0aA:undetectable","5z6mA-2q0aA:24.51"],["7DFR_A_FOLA161_0","DIHYDROFOLATE REDUCTASE","2q0a","POTASSIUM\/SODIUM HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CHANNEL 2","Mus musculus",6,"ILE A 545;ALA A 593;PHE A 580;LEU A 603;ILE A 544;THR A 592","PCG A 401 ( 4.0A);PCG A 401 (-3.8A);None;None;None;PCG A 401 (-2.9A)","1.25A","7dfrA-2q0aA:undetectable","7dfrA-2q0aA:23.38"]]